SUMMARY: Researchers will look for new biomarkers for early diagnosis of hemangiosarcoma. THE PROBLEM: Hemangiosarcoma is a serious and deadly form of cancer that affects all dogs but golden retrievers...

Researchers will explore the use of tiny particles called extracellular vesicles to deliver chemotherapy drugs directly to hemangiosarcoma cancer cells to pave the way for the development of much-needed new treatments.   

Researchers will determine if common heart medications are an effective adjunct therapy for dogs with hemangiosarcoma.

Investigators are assessing the potential for a specific tumor-cell population in canine hemangiosarcoma to sequester drugs within their lysosomes as a novel mechanism of drug resistance.

Researchers will evaluate if trained bio-detection dogs can diagnose hemangiosarcoma from a blood sample.

Researchers are studying if hemangiosarcoma subtypes influence how affected dogs respond to treatment – a step toward precision medicine for these patients.

Researchers will study changes in microRNAs in the blood of dogs enrolled in the Golden Retriever Lifetime Study and diagnosed with hemangiosarcoma to identify early disease biomarkers.

Researchers will investigate the role of a genetic mutation found in about one third of dogs diagnosed with hemangiosarcoma, in an effort to find new therapies for dogs affected by this aggressive and highly metastatic cancer.